Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer

被引:7
|
作者
Zhou, Min [1 ]
Li, Bingshu [1 ]
Liu, Jianfeng [1 ]
Hong, Li [1 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Gynecol & Obstet, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China
关键词
pyroptosis; gynecological cancer; tumor microenvironment; immunotherapy; overall survival; TUMOR-INFILTRATING LYMPHOCYTES; FAVORABLE PROGNOSIS; EXPRESSION; MICROENVIRONMENT; PD-1/PD-L1; INHIBITORS; CD44;
D O I
10.2147/JIR.S344554
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: Pyroptosis is a form of lytic programmed cell death that is associated with the pathogenesis of many tumors. However, the potential roles of pyroptosis-related genes (PRGs) in the tumor microenvironment (TME) remain unclear. Materials and Methods: We systematically described the genetic and transcriptional alterations in PRGs in gynecological cancers. An unsupervised clustering method was used to investigate the molecular subtypes of ovarian cancer (OV) and systematically analyze the TME cell infiltration characteristics. A prognostic signature and nomogram were established to quantify the pyroptosis patterns of individual tumors. We also analyzed the expression levels of eight PRGs in the OV tissues. Results: Two distinct molecular subtypes of OV were identified, and these two distinct molecular subtypes could predict clinicopathological features, prognosis, TME stromal activity, immune infiltrating cells, and immune checkpoints. A prognostic signature was established, and its predictive capability was validated. Low risk score, characterized by activation of immunity, upregulation of programmed death-ligand 1 expression, lower tumor immune dysfunction and exclusion scores, lower tumor mutation burden, and favorable prognosis. These findings suggested that low-risk patients with OV may be more sensitive to immunotherapy. In addition, this signature could effectively predict the response to chemotherapy in patients with OV. Furthermore, a prognostic nomogram was generated, which exhibited superior predictive accuracy. Conclusion: This study highlights the crucial role of PRGs in the TME and may help develop immunotherapies and promote individualized therapeutic strategies for patients with OV.
引用
收藏
页码:7341 / 7358
页数:18
相关论文
共 50 条
  • [31] Genomic analysis of epithelial ovarian cancer
    John Farley
    Laurent L Ozbun
    Michael J Birrer
    Cell Research, 2008, 18 : 538 - 548
  • [32] Genomic analyses of epithelial ovarian cancer
    Farley, John
    Ozbun, Laurent L.
    Birrer, Michael J.
    CELL RESEARCH, 2008, 18 (05) : 538 - 548
  • [33] Chemoprediction in ovarian cancer - genomic approaches
    Hartmann, LC
    Couch, FJ
    Iturria, SJ
    Lu, KH
    Clark, E
    Damokosh, A
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 135 - 135
  • [34] Classification of ovarian cancer: A genomic analysis
    Stany, Michael P.
    Bonome, Tomas
    Wamunyokoli, Fred
    Zorn, Kristen
    Ozbun, Laurent
    Park, Dong-Choon
    Hao, Ke
    Boyd, Jeff
    Sood, Anil K.
    Gershenson, David M.
    Berkowitz, Ross S.
    Mok, Samuel C.
    Birrer, Michael J.
    OVARIAN CANCER: STATE OF THE ART AND FUTURE DIRECTIONS IN TRANSLATIONAL RESEARCH, 2008, 622 : 23 - 33
  • [35] Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
    Xu-Chao Zhang
    Jun Wang
    Guo-Guang Shao
    Qun Wang
    Xiaotao Qu
    Bo Wang
    Christopher Moy
    Yue Fan
    Zayed Albertyn
    Xiayu Huang
    Jingyu Zhang
    Yang Qiu
    Suso Platero
    Matthew V. Lorenzi
    Enrique Zudaire
    Jennifer Yang
    Ying Cheng
    Lin Xu
    Yi-Long Wu
    Nature Communications, 10
  • [36] Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
    Zhang, Xu-Chao
    Wang, Jun
    Shao, Guo-Guang
    Wang, Qun
    Qu, Xiaotao
    Wang, Bo
    Moy, Christopher
    Fan, Yue
    Albertyn, Zayed
    Huang, Xiayu
    Zhang, Jingyu
    Qiu, Yang
    Platero, Suso
    Lorenzi, Matthew V.
    Zudaire, Enrique
    Yang, Jennifer
    Cheng, Ying
    Xu, Lin
    Wu, Yi-Long
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [37] Immunological aspects of ovarian cancer: Therapeutic perspectives
    Nayama, M.
    Collinet, P.
    Salzet, M.
    Vinatier, D.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2016, 45 (09): : 1020 - 1036
  • [38] Specific keynote: Immunological therapy for ovarian cancer
    Berek, JS
    Dorigo, O
    Schultes, B
    Nicodemus, C
    GYNECOLOGIC ONCOLOGY, 2003, 88 (01) : S105 - S109
  • [39] Immunological analogies between ovarian cancer and pregnancy
    Hanssen, S.
    Collinet, P.
    Leblanc, E.
    Salzet, M.
    Vinatier, D.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2013, 42 (03): : 217 - 226
  • [40] BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER
    BOOKMAN, MA
    BEREK, JS
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (04) : 941 - 965